Log In
Print this Print this

sepantronium (YM155)

  Manage Alerts
Collapse Summary General Information
Company Astellas Pharma Inc.
DescriptionSurvivin expression inhibitor
Molecular Target Survivin (BIRC5)
Mechanism of ActionSurvivin inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationNon-Hodgkin's lymphoma (NHL)
Indication DetailsTreat non-Hodgkin's lymphoma (NHL)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today